New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE
This episode discusses new insights into PU.1-mutated agammaglobulinemia, highlighting its role in infections and deficiencies without leukemia. It also covers venetoclax-based induction therapy for younger AML patients, comparing its safety and response rates to intensive…